Retatrutide
Sources
publication, as of 2026-09-29Stale
https://pubmed.ncbi.nlm.nih.gov/42814954/
Retatrutide is a triple-receptor agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. Adults with obesity without diabetes received a once-weekly subcutaneous injection of retatrutide (at a dose of 4 mg, 9 mg, or 12 mg) or placebo for 80 weeks. For weight-related end points, intercurrent events were handled by a treatment-regimen estimand (intention-to-treat [ITT]). The mean percent change in body weight was -17.6% (4-mg dose), -23.7% (9-mg dose), and -25.0% (12-mg dose) versus -3.9% with placebo (differences, -19.8 and -21.0 percentage points, respectively).
N Engl J Med, PMID 42814954, article date 2026-09-29, abstract
registry, as of 2026-08-21Stale
https://clinicaltrials.gov/study/NCT05929066
Protocol section, NCT05929066 TRIUMPH-1, last update posted 2026-08-21
registry, as of 2026-10-08Stale
https://clinicaltrials.gov/study/NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 10000. Conditions Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD). The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardi
ClinicalTrials.gov NCT06383390 protocol and results modules
registry, as of 2026-07-30Stale
https://clinicaltrials.gov/study/NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1946. Conditions Obesity; Cardiovascular Diseases. The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
ClinicalTrials.gov NCT05882045 protocol and results modules
registry, as of 2026-07-30Stale
https://clinicaltrials.gov/study/NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1152. Conditions Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-M
ClinicalTrials.gov NCT05929079 protocol and results modules
registry, as of 2026-07-20Stale
https://clinicaltrials.gov/study/NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Obesity. The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
ClinicalTrials.gov NCT06662383 protocol and results modules
registry, as of 2026-03-03Stale
https://clinicaltrials.gov/study/NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 643. Conditions Obesity. This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week
ClinicalTrials.gov NCT06859268 protocol and results modules
registry, as of 2026-06-09Stale
https://clinicaltrials.gov/study/NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 600. Conditions Obesity; Overweight. The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.
ClinicalTrials.gov NCT07357415 protocol and results modules
registry, as of 2026-09-25Stale
https://clinicaltrials.gov/study/NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 586. Conditions Obesity; Overweight; Chronic Low Back Pain (CLBP). The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
ClinicalTrials.gov NCT07035093 protocol and results modules
registry, as of 2026-01-21Stale
https://clinicaltrials.gov/study/NCT05931367
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 445. Conditions Obesity; Overweight; Osteo Arthritis Knee. The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
ClinicalTrials.gov NCT05931367 protocol and results modules
registry, as of 2026-04-17Stale
https://clinicaltrials.gov/study/NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 250. Conditions Obesity; Overweight. The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
ClinicalTrials.gov NCT07232719 protocol and results modules
registry, as of 2026-03-12Stale
https://clinicaltrials.gov/study/NCT07467447
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight. Overall status RECRUITING. Phases PHASE2. Lead sponsor Hudson Biotech. Enrollment 300. Conditions Obesity. Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes)
ClinicalTrials.gov NCT07467447 protocol and results modules
registry, as of 2025-11-25Stale
https://clinicaltrials.gov/study/NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 146. Conditions Overweight or Obesity; CKD; Type 2 Diabetes. The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
ClinicalTrials.gov NCT05936151 protocol and results modules
registry, as of 2026-08-06Stale
https://clinicaltrials.gov/study/NCT07629401
Pre-approval Expanded Access of Retatrutide (LY3437943). Overall status AVAILABLE. Phases not stated. Lead sponsor Eli Lilly and Company. Conditions Obesity; Obesity-related Complications. Provide pre-approval single-patient expanded access of retatrutide (LY3437943), an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management, for adults with severe obesity (body mass index \[BMI\] greater than or equal to \[≥\]35 kilo
ClinicalTrials.gov NCT07629401 protocol and results modules